Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03085186
Previous Study | Return to List | Next Study

Treatment With Crizotinib Single Patient Expanded Access IND 134375

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03085186
Expanded Access Status : No longer available
First Posted : March 21, 2017
Last Update Posted : August 29, 2017
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Jean M. Tersak, M.D., University of Pittsburgh

Tracking Information
First Submitted Date March 14, 2017
First Posted Date March 21, 2017
Last Update Posted Date August 29, 2017
 
Descriptive Information
Brief Title Treatment With Crizotinib Single Patient Expanded Access IND 134375
Official Title Treatment With Crizotinib Single Patient Expanded Access IND 134375
Brief Summary

Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.

Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.

Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Inflammatory Myofibroblastic Tumour
Intervention Drug: Crizotinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Eligibility Criteria

Inclusion Criteria:

  • This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour

Exclusion Criteria:

  • Not applicable as Expanded Access only includes one patient
Sex/Gender
Sexes Eligible for Study: Male
Ages 2 Years to 2 Years   (Child)
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03085186
Other Study ID Numbers PRO17030033
Responsible Party Jean M. Tersak, M.D., University of Pittsburgh
Study Sponsor Jean M. Tersak, M.D.
Collaborators Pfizer
Investigators Not Provided
PRS Account University of Pittsburgh
Verification Date August 2017